Floatz logo

FILGRASTIM

Iris Melanoma

National Cancer Institute (NCI)protein_peptidePhase 3Dormant
BB
67/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
53/ 100
Competitive Position
95/ 100

Competitive context

6 Active assets in the Iris Melanoma cohort.

Asset / SponsorPhaseRating
Tyrosinase Peptide
National Cancer Institute (NCI)
Phase 3BB
FLUTICASONE
National Cancer Institute (NCI)
Phase 3BB
Sargramostim
National Cancer Institute (NCI)
Phase 3BB
Cyclophosphamide
H. Lee Moffitt Cancer Center and Research Institute
Phase 2B
Ifa
National Cancer Institute (NCI)
Phase 2B

View all 32 →

Same molecule, other indications

FILGRASTIM is also rated in:

plasma cell myelomaDormant
BBB
Indicative ·
79 / 100
View asset →
Burkitt lymphomaDormant
BBB
Indicative ·
78 / 100
View asset →
Hodgkins lymphomaDormant
BBB
Indicative ·
76 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →